Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Treatment Subprotocol E: Osimertinib in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR
NCT06303167Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in malignant solid neoplasm, lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Jan 2016; status: active, not recruiting.
02
Drugs
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06303167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303167.